BioPorto has reported its results for Q121, which included DKK5.6m in sales from all its research use only products. This is up from Q120 (DKK4.2m) but comparable to Q119 (DKK5.5m). The biggest near-term driver for the company’s revenue will be the pending results of its pivotal paediatric acute kidney injury (AKI) clinical study, which is slated to complete in summer 2021, and the subsequent regulatory submission to the FDA for De Novo 510(k) clearance.
13 May 2021
BioPorto Diagnostics - Focused on the upcoming paediatric AKI results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BioPorto Diagnostics - Focused on the upcoming paediatric AKI results
- Published:
13 May 2021 -
Author:
Dr Nathaniel Calloway -
Pages:
5
BioPorto has reported its results for Q121, which included DKK5.6m in sales from all its research use only products. This is up from Q120 (DKK4.2m) but comparable to Q119 (DKK5.5m). The biggest near-term driver for the company’s revenue will be the pending results of its pivotal paediatric acute kidney injury (AKI) clinical study, which is slated to complete in summer 2021, and the subsequent regulatory submission to the FDA for De Novo 510(k) clearance.